Do you want to read an article? Please log in or register.
Safety of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis: Global Pharmacovigilance Data
Pulmonary Fibrosis
RECOMMENDED
Related content
RECOMMENDED
Pulmonary Fibrosis
Nintedanib plus Sildenafil in Patients with Idiopathic Pulmonary Fibrosis
N Engl J Med.
Kolb M, Raghu G, Wells AU, Behr J, Richeldi L, Schinzel B, Quaresma M, Stowasser S, Martinez FJ; INSTAGE Investigators
doi: 10.1056/NEJMoa1811737.
RECOMMENDED
Pulmonary Fibrosis
Patient and site characteristics associated with pirfenidone and nintedanib use in the United States; an analysis of idiopathic pulmonary fibrosis patients enrolled in the Pulmonary Fibrosis Foundation Patient Registry
★ 1
Recommended by
Dr Martin Frey, Faculty Member
★ 2
Recommended by
Dr Marcus Hesse, Faculty Member
Respir Res.
Holtze CH, Freiheit EA, Limb SL, Stauffer JL, Raimundo K, Pan WT, Flaherty KR, Kim HJ
doi: 10.1186/s12931-020-1315-4.
RECOMMENDED
Pulmonary Fibrosis
Patient expectations, experiences and satisfaction with nintedanib and pirfenidone in idiopathic pulmonary fibrosis: a quantitative study
★ 2
Recommended by
Dr Martin Frey, Faculty Member
Respir Res.
Moor CC, Mostard RLM, Grutters JC, Bresser P, Aerts JGJV, Dirksen CD, Kimman ML, Wijsenbeek MS
doi: 10.1186/s12931-020-01458-1.
RECOMMENDED
Pulmonary Fibrosis
Efficacy and safety of nintedanib in patients with idiopathic pulmonary fibrosis who are elderly or have comorbidities
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
Respir Res
Glaspole I, Bonella F, Bargagli E, Glassberg MK, Caro F, Stansen W, Quaresma M, Orsatti L, Bendstrup E
doi: 10.1186/s12931-021-01695-y
RECOMMENDED
Pulmonary Fibrosis
Nintedanib Treatment for Idiopathic Pulmonary Fibrosis Patients Who Have Been Switched from Pirfenidone Therapy: A Retrospective Case Series Study
★ 1
Recommended by
Dr Martin Frey, Faculty Member
★ 2
Recommended by
Dr Marcus Hesse, Faculty Member
J Clin Med.
Vianello A, Salton F, Molena B, Turato C, Graziani ML, Braccioni F, Frassani V, Sella D, Pretto P, Paladini L, Sukthi A, Confalonieri M
doi: 10.3390/jcm9020422.
Pulmonary Fibrosis
Biomarkers of extracellular matrix turnover in patients with idiopathic pulmonary fibrosis given nintedanib (INMARK study): a randomised, placebo-controlled study
Lancet Respir Med.
Maher TM, Stowasser S, Nishioka Y, White ES, Cottin V, Noth I, Selman M, Rohr KB, Michael A, Ittrich C, Diefenbach C, Jenkins RG, INMARK trial investigators.
doi: 10.1016/S2213-2600(19)30255-3.
RECOMMENDED
Pulmonary Fibrosis
Hospital-Based Resource Use and Costs Among Patients With Idiopathic Pulmonary Fibrosis Enrolled in the Idiopathic Pulmonary Fibrosis Prospective Outcomes (IPF-PRO) Registry
★ 1
Recommended by
Dr Martin Frey, Faculty Member
Chest.
Fan Y, Bender SD, Conoscenti CS, Davidson-Ray L, Cowper PA, Palmer SM, de Andrade JA, IPF-PRO™ Registry investigators.
doi: 10.1016/j.chest.2019.12.041.
RECOMMENDED
Pulmonary Fibrosis
Comparative outcomes in patients receiving pirfenidone or nintedanib for idiopathic pulmonary fibrosis
★ 2
Recommended by
Dr Martin Frey, Faculty Member
★ 2
Recommended by
Dr Marcus Hesse, Faculty Member
Respir Res
Belhassen M, Dalon F, Nolin M, Van Ganse E
doi: 10.1186/s12931-021-01714-y
RECOMMENDED
Pulmonary Fibrosis
Adoption of the Anti-Fibrotic Medications Pirfenidone and Nintedanib for Patients with Idiopathic Pulmonary Fibrosis
★ 2
Recommended by
Dr Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
Ann Am Thorac Soc
Dempsey TM, Payne S, Sangaralingham L, Yao X, Shah ND, Limper AH
doi: 10.1513/AnnalsATS.202007-901OC